© 2020 MJH Life Sciences and OncLive. All rights reserved.
July 4th 2020, 10:00am
Shannon N. Westin, MD, MPH, discusses the rationale for administering
the maintenance therapy in this setting and the broader potential of regimens
combining PARP with other therapies.
June 24th 2020, 10:12pm
Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.
June 24th 2020, 2:13pm
Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.
June 23rd 2020, 3:02pm
Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.
June 20th 2020, 1:00am
Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.
June 20th 2020, 12:12am
Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.
June 17th 2020, 5:51pm
Naveen Pemmaraju, MD, discusses what the early data with eprenetapopt in combination with azacitidine could mean for the future in MDS and AML.
June 16th 2020, 7:31pm
Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
June 15th 2020, 9:30pm
Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.
June 15th 2020, 9:21pm
Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.